CD40 agonist mitazalimab not checked
Alligator Bioscience AB · ADC-1013 · JNJ-64457107
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Mitazalimab administered intravenously every 14 days in combination with standard of care chemotherapy modified FOLFIRINOX.”In the company’s words, NCT04888312 on ClinicalTrials.gov
- Main trialPhase 1/2
- “Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma.”In the company’s words, NCT04888312 on ClinicalTrials.gov
- Other names
- ADC-1013 · JNJ-64457107
Other drugs for Metastatic Pancreatic Ductal Adenocarcinoma
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 1 Jun 2026 | Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026